Salvage radiotherapy for prostate cancer

Finding a way forward using radiobiological modeling

Nitin Ohri, Xinglei Shen, Robert B. Den, Adam P. Dicker, Edouard J. Trabulsi, Timothy N. Showalter

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: Recent modeling efforts, based on reported outcomes following salvage radiotherapy (SRT) for prostate cancer, predict the likelihood of biochemical control (tumor control probability, TCP) as a function of pre-treatment prostate specific antigen (PSA ) and SRT dose. Similar instruments predict the risk of grade ≥ 3 late toxicity (normal tissue complication probability, NTCP) as a function of SRT dose. Here we explore how changes in the parameters of those models might affect the optimal SRT dose and clinical outcomes. Results: Improving the safety of SRT increased the optimal SRT dose, while radiosensitization decreased the optimal dose. Both changes were predicted to increase the probability of biochemical control and decrease late toxicity rates. Increasing the cure rate achievable with SRT (e.g., improving patient selection or combining SRT with effective systemic therapy) provided the greatest gains in TCP. Adoption of a hypofractionated SRT schedule was predicted to improve both biochemical control and late toxicity. Methods and Materials: Baseline TCP and NTCP model parameters were established in a previous report. Pre-treatment PSA was set at 0.4 ng/mL. Model parameters were modified to explore four scenarios: (1) improving the safety of SRT, (2) increasing tumor cell radiosensitivity, (3) increasing the cure rate achievable with SRT and (4) adoption of hypofractionated SRT schedules. The "optimal" SRT dose, defined as the dose that maximized the likelihood of achieving biochemical control without causing late toxicity, was identified for each scenario. Conclusions: Modeling exercises demonstrate the significant gains that may be achieved with improved implementation of SRT for prostate cancer. Strategies to realize the effects modeled in this report should be explored in clinical trials.

Original languageEnglish (US)
Pages (from-to)1449-1453
Number of pages5
JournalCancer Biology and Therapy
Volume13
Issue number14
DOIs
StatePublished - Dec 2012

Fingerprint

Prostatic Neoplasms
Radiotherapy
Prostate-Specific Antigen
Neoplasms
Appointments and Schedules
Safety
Radiation Tolerance
Patient Selection
Therapeutics
Clinical Trials

Keywords

  • NTCP
  • Prostate cancer
  • Salvage radiotherapy
  • TCP

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Molecular Medicine
  • Pharmacology

Cite this

Salvage radiotherapy for prostate cancer : Finding a way forward using radiobiological modeling. / Ohri, Nitin; Shen, Xinglei; Den, Robert B.; Dicker, Adam P.; Trabulsi, Edouard J.; Showalter, Timothy N.

In: Cancer Biology and Therapy, Vol. 13, No. 14, 12.2012, p. 1449-1453.

Research output: Contribution to journalArticle

Ohri, Nitin ; Shen, Xinglei ; Den, Robert B. ; Dicker, Adam P. ; Trabulsi, Edouard J. ; Showalter, Timothy N. / Salvage radiotherapy for prostate cancer : Finding a way forward using radiobiological modeling. In: Cancer Biology and Therapy. 2012 ; Vol. 13, No. 14. pp. 1449-1453.
@article{fad13c492fa247da9ecf4e62823744c7,
title = "Salvage radiotherapy for prostate cancer: Finding a way forward using radiobiological modeling",
abstract = "Purpose: Recent modeling efforts, based on reported outcomes following salvage radiotherapy (SRT) for prostate cancer, predict the likelihood of biochemical control (tumor control probability, TCP) as a function of pre-treatment prostate specific antigen (PSA ) and SRT dose. Similar instruments predict the risk of grade ≥ 3 late toxicity (normal tissue complication probability, NTCP) as a function of SRT dose. Here we explore how changes in the parameters of those models might affect the optimal SRT dose and clinical outcomes. Results: Improving the safety of SRT increased the optimal SRT dose, while radiosensitization decreased the optimal dose. Both changes were predicted to increase the probability of biochemical control and decrease late toxicity rates. Increasing the cure rate achievable with SRT (e.g., improving patient selection or combining SRT with effective systemic therapy) provided the greatest gains in TCP. Adoption of a hypofractionated SRT schedule was predicted to improve both biochemical control and late toxicity. Methods and Materials: Baseline TCP and NTCP model parameters were established in a previous report. Pre-treatment PSA was set at 0.4 ng/mL. Model parameters were modified to explore four scenarios: (1) improving the safety of SRT, (2) increasing tumor cell radiosensitivity, (3) increasing the cure rate achievable with SRT and (4) adoption of hypofractionated SRT schedules. The {"}optimal{"} SRT dose, defined as the dose that maximized the likelihood of achieving biochemical control without causing late toxicity, was identified for each scenario. Conclusions: Modeling exercises demonstrate the significant gains that may be achieved with improved implementation of SRT for prostate cancer. Strategies to realize the effects modeled in this report should be explored in clinical trials.",
keywords = "NTCP, Prostate cancer, Salvage radiotherapy, TCP",
author = "Nitin Ohri and Xinglei Shen and Den, {Robert B.} and Dicker, {Adam P.} and Trabulsi, {Edouard J.} and Showalter, {Timothy N.}",
year = "2012",
month = "12",
doi = "10.4161/cbt.22006",
language = "English (US)",
volume = "13",
pages = "1449--1453",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "14",

}

TY - JOUR

T1 - Salvage radiotherapy for prostate cancer

T2 - Finding a way forward using radiobiological modeling

AU - Ohri, Nitin

AU - Shen, Xinglei

AU - Den, Robert B.

AU - Dicker, Adam P.

AU - Trabulsi, Edouard J.

AU - Showalter, Timothy N.

PY - 2012/12

Y1 - 2012/12

N2 - Purpose: Recent modeling efforts, based on reported outcomes following salvage radiotherapy (SRT) for prostate cancer, predict the likelihood of biochemical control (tumor control probability, TCP) as a function of pre-treatment prostate specific antigen (PSA ) and SRT dose. Similar instruments predict the risk of grade ≥ 3 late toxicity (normal tissue complication probability, NTCP) as a function of SRT dose. Here we explore how changes in the parameters of those models might affect the optimal SRT dose and clinical outcomes. Results: Improving the safety of SRT increased the optimal SRT dose, while radiosensitization decreased the optimal dose. Both changes were predicted to increase the probability of biochemical control and decrease late toxicity rates. Increasing the cure rate achievable with SRT (e.g., improving patient selection or combining SRT with effective systemic therapy) provided the greatest gains in TCP. Adoption of a hypofractionated SRT schedule was predicted to improve both biochemical control and late toxicity. Methods and Materials: Baseline TCP and NTCP model parameters were established in a previous report. Pre-treatment PSA was set at 0.4 ng/mL. Model parameters were modified to explore four scenarios: (1) improving the safety of SRT, (2) increasing tumor cell radiosensitivity, (3) increasing the cure rate achievable with SRT and (4) adoption of hypofractionated SRT schedules. The "optimal" SRT dose, defined as the dose that maximized the likelihood of achieving biochemical control without causing late toxicity, was identified for each scenario. Conclusions: Modeling exercises demonstrate the significant gains that may be achieved with improved implementation of SRT for prostate cancer. Strategies to realize the effects modeled in this report should be explored in clinical trials.

AB - Purpose: Recent modeling efforts, based on reported outcomes following salvage radiotherapy (SRT) for prostate cancer, predict the likelihood of biochemical control (tumor control probability, TCP) as a function of pre-treatment prostate specific antigen (PSA ) and SRT dose. Similar instruments predict the risk of grade ≥ 3 late toxicity (normal tissue complication probability, NTCP) as a function of SRT dose. Here we explore how changes in the parameters of those models might affect the optimal SRT dose and clinical outcomes. Results: Improving the safety of SRT increased the optimal SRT dose, while radiosensitization decreased the optimal dose. Both changes were predicted to increase the probability of biochemical control and decrease late toxicity rates. Increasing the cure rate achievable with SRT (e.g., improving patient selection or combining SRT with effective systemic therapy) provided the greatest gains in TCP. Adoption of a hypofractionated SRT schedule was predicted to improve both biochemical control and late toxicity. Methods and Materials: Baseline TCP and NTCP model parameters were established in a previous report. Pre-treatment PSA was set at 0.4 ng/mL. Model parameters were modified to explore four scenarios: (1) improving the safety of SRT, (2) increasing tumor cell radiosensitivity, (3) increasing the cure rate achievable with SRT and (4) adoption of hypofractionated SRT schedules. The "optimal" SRT dose, defined as the dose that maximized the likelihood of achieving biochemical control without causing late toxicity, was identified for each scenario. Conclusions: Modeling exercises demonstrate the significant gains that may be achieved with improved implementation of SRT for prostate cancer. Strategies to realize the effects modeled in this report should be explored in clinical trials.

KW - NTCP

KW - Prostate cancer

KW - Salvage radiotherapy

KW - TCP

UR - http://www.scopus.com/inward/record.url?scp=84870712795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870712795&partnerID=8YFLogxK

U2 - 10.4161/cbt.22006

DO - 10.4161/cbt.22006

M3 - Article

VL - 13

SP - 1449

EP - 1453

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 14

ER -